skip to content
Detailed Quote
5i Report
Rating
B

Review of Knight Therapeutics

SEP 03, 2021 - For years, GUD sat on over $700 million in cash and investors awaited big acquisitions. GUD has now made two after investors simply got ‘bored’ of the stock. We do not think management
has done anything wrong, but the delay caused high opportunity costs for investors. Rating downgraded to ‘B’.

Download Report
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions

Q: I am considering sell GUD and buying IBB and/or IHI and/or VEEV and/or GH. Risk is not an issue and I am okay with US stocks as well as Canadian. Your comments would be appreciated.

Thanks for your service

Read Answer Asked by Ozzie on October 04, 2021

Q: Hey Team,

I realize you have moved on from GUD, and I can understand, although I feel that you may have given up just before the value realization.

Am I reading their statements correctly in that they have over $5 per share on just current assets, and another $5 in long term assets?

This is on an arguably improving landscape for the company over the next 12 months?
Seems way too cheap to ignore, when fundamentals have turned positive, no?

Read Answer Asked by JAIME on September 23, 2021
Insiders
Share Information
News and Media